Before the Open (Oct 23)

Posted on by Jason Leavitt

Good morning. Happy Monday. Hope you had a good weekend.
The Asian/Pacific markets closed mixed. Japan, South Korea, India, Indonesia and Thailand posted gains; Hong Kong and the Philippines posted losses. Europe, Asia and the Middle East currently lean to the downside. Greece and Saudi Arabia are down more than 1%; Turkey, Kenya, Spain and the Czech Republic are also down. Poland, France and Finland are up. Futures in the States point towards a slight positive open for the cash market.
—————
VIDEO: My Favorite Intermediate Term Trading Setup
—————
The dollar is up. Oil and copper are up. Gold and silver are up. Bonds are up.
Stock headlines from barchart.com…
Illumina (ILMN +2.29%) was upgraded to ‘Buy’ from ‘Hold’ at Deutsche Bank with a price target of $250.
Dr. Pepper Snapple Group (DPS -0.31%) was upgraded to ‘Outperform’ from ‘Market Perform’ at Wells Fargo Securities with a price target of $98.
General Electric (GE +1.06%) was downgraded to ‘Underweight’ from ‘Equal-Weight’ at Morgan Stanley with a price target of $22.
JB Hunt Transport Services (JBHT +1.71%) was upgraded to ‘Buy’ from ‘Neutral’ at UBS with a price target of $126.
Biogen (BIIB -1.26%) was downgraded to ‘Neutral’ from ‘Buy’ at Citigroup.
Science Applications International (SAIC +1.49%) was upgraded to ‘Buy’ from ‘Neutral’ at Citigroup with a price target of $82.
Equifax (EFX -0.49%) was downgraded to ‘Sector Perform’ from ‘Outperform’ at RBC Capital Markets.
Southern Copper (SCCO -0.37%) was downgraded to ‘Sector Underperform’ from ‘Sector Perform’ at Scotiabank with a price target of $41.
Schmitt Industries (SMIT -0.55%) may move higher this morning after GAMCO Investors reported an 8.26% stake in the company, making it the third-largest equity holder.
Johnson & Johnson (JNJ +0.25%) said its Janssen Biotech company received FDA approval for its SIMPONI ARIA drug for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis.
DBV Technologies SA (DBVT +1.95%) plunged 50% in after-hours trading after its peanut-allergy patch failed to reach a primary endpoint in a Phase 3 trial. Competitor Aimmune Therapeutics (AIMT -0.23%) surged 60% in after-hours trading on the news.
—————
Join our email list – get technical research reports sent directly to you.
—————
Today’s Economic Calendar
8:30 Chicago Fed National Activity Index
Other…
today’s upgrades/downgrades from briefing.com
this week’s Earnings from Morningstar
this week’s Economic Numbers/Reports powered by ECONODAY

2 thoughts on “Before the Open (Oct 23)”

  1. The frequent use (or overuse) of the term “average” always reminds me of an economics professor saying, (forgive my vulgarity, please), “Speaking of averages, the average person has one tit and one testicle.” It always makes me smile.
    Look for 100% returns, not 4% (average) as I do. There are winners out there I am told. WE pikers are not to be followed as we search for average returns.

Leave a Reply